IRCT20100228003449N33 IRCT 2024-12-11 Tehran University of Medical Sciences Magnesium sulfate and reducing sedative requirement Evaluation of magnesium sulfate efficacy in reducing sedative requirement in patients under mechanical ventilation 2024-12-01 anticipated 78 Complete https://irct.ir/trial/80452 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization is done by the method of random blocks. According to the sample size, four patients are included in each block. Random groups are AABB, BBAA, ABBA, ABAB, BABA, BAAB. Random numbers will be generated by Excel software, Blinding description: Intravenous magnesium sulfate and saline will be prepared and labeled by a technician not involved in the study. The patient and research members are unaware of the contents of the syringes. 2-3 Management of pain, agitation/sedation and delirium in mechanically ventilated patients. Intervention 1: Control group: In addition to the sedation protocol, patients will receive placebo (saline). Intervention 2: Intervention group: In addition to the sedation protocol, patients will receive intravenous magnesium sulfate. The target serum level of magnesium in this group is 3 mg/dL. The dose of magnesium for each patient will be calculated based on the rule of thumb. According to this rule, every 1 gram of magnesium sulfate leads to an increase of 0.18 mg/dL in the serum level of magnesium. One third of the calculated dose will be infused as a bolus within 30 minutes and the rest within 24 hours. Each 1 gram of intravenous magnesium sulfate will be diluted in 50 ml of normal saline and infused at least within 1 hour. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information.